FinTrust Capital Advisors’s Vir Biotechnology VIR Stock Holding History

FinTrust Capital Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$105	Hold	14	–	–	﹤0.01%	1349
2024 Q2	$125	Hold	14	–	–	﹤0.01%	1345
2024 Q1	$142	Hold	14	–	–	﹤0.01%	1245
2023 Q4	$141	Hold	14	–	–	﹤0.01%	1222
2023 Q3	$132	Sell	14 -2,500	-99%	-$35.7K	﹤0.01%	1201
2023 Q2	$63.6K	Hold	2,514	–	–	0.02%	409
2023 Q1	$63.6K	Hold	2,514	–	–	0.02%	407
2022 Q4	$63.6K	Hold	2,514	–	–	0.02%	408
2022 Q3	$54K	Buy	2,514 +2,499	+16,660%	+$63.5K	0.01%	498
2022 Q2	$0	Sell	15 -2,000	-99%	-$46.7K	﹤0.01%	1316
2022 Q1	$51K	Hold	2,015	–	–	0.01%	561
2021 Q4	$84K	Buy	+2,015	New	+$78.9K	0.02%	457
2021 Q3	–	Sell	-500	Closed	-$24K	–	1218
2021 Q2	$24K	Hold	500	–	–	0.01%	722
2021 Q1	$26K	Buy	+500	New	+$26.9K	0.01%	656

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

FinTrust Capital Advisors's VIR Position: Q3 2024 in Review

FinTrust Capital Advisors held its Vir Biotechnology (VIR) position steady in Q3 2024 at 14 shares worth $105. The position accounts for ﹤0.01% of the portfolio, ranked #1349.

FinTrust Capital Advisors first reported a position in VIR in Q1 2021 and has held it in 14 quarters since. The position peaked at $84K in Q4 2021. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

FinTrust Capital Advisors held 14 shares of Vir Biotechnology worth $105 as of Q3 2024.
FinTrust Capital Advisors left its Vir Biotechnology share count unchanged in Q3 2024.
Vir Biotechnology made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1349 holding.
FinTrust Capital Advisors first reported a position in Vir Biotechnology in Q1 2021 and has held it in 14 quarters since.
FinTrust Capital Advisors's Vir Biotechnology position peaked at $84K in Q4 2021.
197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.